GiveWell tends to be known for its work in areas like malaria prevention, water treatment, and nutrition. But as our research team has grown, so has our ability to search for cost-effective programs across a much wider range of issues.

Serious health problems, such as lack of medical oxygen and stockouts of essential medicines at health facilities, affect millions of people in low-income countries. There may be highly cost-effective solutions to these problems that haven’t been thoroughly evaluated or adequately funded. One of the ways GiveWell is searching for these solutions is through the new areas research subteam, which investigates programs in cause areas GiveWell hasn’t historically focused on.

In this episode, GiveWell co-founder and CEO Elie Hassenfeld speaks with Senior Program Officer Dan Brown about GiveWell’s new areas research subteam and three grants that illustrate the team’s work.

Elie and Dan discuss:

• Evaluating whether electronic tracking can improve access to health supplies: In many low- and middle-income countries, health facilities track their medicine supplies on paper, with stock counted roughly once a month for only a subset of products. As a result, staff may be less able to accurately predict inventory levels. This can lead to stockouts, making it more difficult for people to access the treatment they need, or to surplus commodities, which could result in expired medicines. GiveWell is funding the Clinton Health Access Initiative (CHAI), mSupply Foundation, and University of California, Berkeley to implement an electronic supply chain management system in health facilities in Laos and conduct a randomized controlled trial measuring whether the system reduces stockouts and improves patients’ access to the treatments they need. If we learn that more people are able to access treatment as a result, funding the rollout of this type of software in countries facing higher burdens of disease could be a cost-effective strategy for reducing mortality. 
• Supporting a new approach to medical oxygen production: Medical oxygen is essential for treating severe pneumonia, malaria, and many other health conditions—yet access in low-income countries remains limited. GiveWell is funding PATH to assess the market viability of a recently developed oxygen-producing device that appears to require far less maintenance than existing technology. This is an early-stage investment focused on understanding manufacturing costs and potential demand. PATH’s work will run concurrently with research funded by other organizations assessing whether the device works effectively in real-world conditions in low-income countries. We’re also investigating other opportunities to improve the ability to diagnose low oxygen and increase access to a reliable oxygen supply in health facilities. 
• Investigating a caregiver training program for newborn health: Noora Health’s Care Companion Program trains family members in practices that support maternal and newborn health, including skin-to-skin contact, breastfeeding techniques, and how to recognize illness warning signs. The existing evidence base for these practices is limited to one study without a control group (making it difficult to assess if the practices actually caused the results), so GiveWell is funding two studies in India: a pilot study assessing intermediate health outcomes like sepsis and umbilical cord infections that are linked to newborn mortality, and a larger randomized controlled trial measuring the program’s effect on neonatal mortality. We expect that these studies will provide additional evidence needed to assess whether to fund the program at scale, potentially reducing childhood deaths.

These grants reflect just a few of the ways GiveWell’s research is expanding to identify more high-impact opportunities to help people. GiveWell is hiring to expand our research team further—including positions on the new areas subteam—so we can cover more ground and ultimately direct more donor funding faster to programs where it can do extraordinary good.

Visit our All Grants Fund page to learn more about how you can support this work, and listen or subscribe to our podcast for our latest updates.

This episode was recorded on June 12, 2026, and represents our best understanding at that time.

In September 2025, we created a livelihoods research subteam to specifically focus on programs that increase the economic well-being of people in extreme poverty. While we have evaluated and funded livelihoods programs throughout GiveWell’s history, we now have a dedicated program officer overseeing this portfolio, which has allowed us to build on and deepen that work. 

Historically, GiveWell has predominantly focused on health-related programs. Diseases like malaria, diarrhea, and pneumonia can be prevented fairly cheaply, and the evidence for health programs is often strong relative to other areas. As our research team has grown, we’ve been building capacity to explore programs that increase people’s incomes, where the long-term impact is often more challenging to measure and effectiveness differs from context to context.   

In this episode, GiveWell co-founder and CEO Elie Hassenfeld speaks with Senior Program Officer Adam Salisbury about GiveWell’s expanding work on livelihoods programs, which programs might be the most cost-effective, and research we’re funding to help answer some key questions. 

Elie and Adam discuss:

• Testing variations of cash transfers: GiveDirectly’s flagship cash transfer program currently falls below our cost-effectiveness threshold for livelihoods interventions, but it has a proven ability to scale. We funded three pilots to test whether specific program adaptations could improve cost-effectiveness enough to meet our threshold: (1) pairing small grants to local businesses with household cash transfers so vendors can stock up to meet new demand, (2) timing cash transfers to coincide with the construction of a new footbridge so recipients can access markets more easily, and (3) targeting cash transfers to the poorest young adults, who may be at a stage in their lives where a large lump sum transfer might be especially impactful.
• Exploring poverty graduation programs: Poverty graduation programs provide extremely poor households with a tool to generate income, such as a sewing machine, along with training and small amounts of money or food so that families have what they need without selling the asset. Evidence shows that these programs increase incomes over the first couple of years, and more recent evidence suggests these effects can persist for five years or longer. We are considering grants for research to assess which program designs are most cost-effective, whether income increases hold up over even longer time periods, and whether the programs can be implemented effectively at scale. Because around two-thirds of poverty graduation programs are now delivered by governments rather than NGOs, we are also exploring opportunities to support these programs by providing technical assistance to governments. 
• Funding research to address key uncertainties: By funding research directly tied to programs we are considering supporting, we aim to make better funding decisions and increase donors’ impact. For example, we had a consultant scrutinize the original data from a randomized controlled trial of GiveDirectly’s flagship program in Kenya that showed positive economic effects in the broader community—and the research held up. We’re now funding other research to assess whether the results can be generalized and considering studies to learn whether their effects persist beyond a few years.

GiveWell is expanding our search for highly cost-effective ways to help people in new areas this year by hiring for new research positions, including a senior livelihoods researcher. As the livelihoods team grows, we aim to evaluate more of the areas in the space, including expanding financial access, improving agricultural activity, and looking at humanitarian response efforts—to make better-informed decisions about where donor funding can do the most good.

Visit our All Grants Fund page to learn more about how you can support this work, and listen or subscribe to our podcast for our latest updates.

This episode was recorded on May 26, 2026 and represents our best understanding at that time.

Anemia, which is commonly caused by iron deficiency, can cause fatigue, cognitive impairment, and complications during pregnancy—and it affects roughly a quarter of the world’s population. Over the last decade, GiveWell has directed nearly $50 million to programs to address this health issue. 

Because of the large number of people affected and the low cost to provide people with iron, we are evaluating additional iron fortification and supplementation programs to potentially increase our grantmaking in this area. At the same time, it has been difficult to determine exactly how much providing people with additional iron improves their lives. GiveWell’s growing research capacity is allowing us to study the programs we’ve funded and to support new research, then to use what we learn to continue improving our funding decisions.

In this episode, GiveWell co-founder and CEO Elie Hassenfeld speaks with Researcher Andrew Martin about GiveWell’s work on iron: why the evidence is more complicated than it might seem, what we’ve learned from years of funding iron programs, and what’s ahead.

Elie and Andrew discuss:

• The evidence for iron: Anemia is a significant problem, but it can be hard to determine the exact magnitude of the benefit that comes from addressing it. In addition, current definitions of anemia, which can be caused by iron deficiency, are based on statistical data about typical hemoglobin levels rather than on people’s symptoms. GiveWell is supporting a randomized controlled trial in Bangladesh that aims to address this by measuring how providing additional iron affects perceived fatigue and other health outcomes—helping determine measurable thresholds at which people experience significant symptoms. We think the findings could reshape our understanding of how anemia affects people's lives and improve our anemia-related grantmaking.
• Looking back at Fortify Health’s progress: Fortify Health partners with wheat flour mills in India to fortify flour with iron and other micronutrients. After earlier grants to Fortify Health providing general support, GiveWell made a larger $8.2 million grant in 2021. At the time GiveWell made this grant, Fortify Health was working with seven mills and reaching roughly 350,000 people per year. Over the next three years, it expanded to 125 open-market mills producing more than 30 times more flour (see chart below) at about half the cost per person reached of our original estimate. We now estimate that our 2021 grant was about twice as cost-effective as we initially projected. Based on this track record, we recently renewed our support to Fortify Health with a $10 million two-year grant.
• What’s next for GiveWell’s research into iron: GiveWell currently supports two iron programs in India: Fortify Health’s work expanding iron fortification of wheat flour and Evidence Action’s iron and folic acid supplementation program for schoolchildren. To date, GiveWell has not funded iron fortification or supplementation programs in Africa, despite the region’s high anemia burden, in part because of concerns about potential harm from iron interventions in high-malaria settings. To help expand our work in this area, we issued a request for information for iron programs earlier this year—focusing on lower-malaria contexts—and are currently evaluating responses. We’re also considering support for historical research studying countries that have introduced fortification programs to help assess the long-term income effects of providing iron. 

GiveWell’s research on iron supplementation and fortification programs exemplifies this moment in GiveWell’s evolution: The research capacity and track record we’ve built are now enabling us to assess past grants, build and evaluate the evidence base, and expand our support of new cost-effective ways to help people in need.

Visit our All Grants Fund page to learn more about how you can support this work, and listen or subscribe to our podcast for our latest updates.

To learn more about how we’re learning and improving by analyzing past grants, like the one described in this episode, join our webinar on June 9. Elie will moderate a conversation with Program Directors Alex Cohen and Julie Faller about our grant lookbacks methodology, what we’ve learned, and how the findings are informing our grantmaking. Learn more and register.

This episode was recorded on May 15, 2026 and represents our best understanding at that time.

GiveWell’s research doesn’t end once we’ve made a grant. We evaluate a subset of completed grants, comparing what we thought would happen to what actually took place, then try to use what we learn to improve our future funding decisions. Over the past year, we’ve formalized and expanded this work, publishing comprehensive “lookbacks” for select grants.

A recent lookback on grants GiveWell made to fund insecticide-treated net distributions supported by the Against Malaria Foundation (AMF) in the Democratic Republic of Congo (DRC) illustrates the growing capacity of GiveWell’s research team. We drew on multiple independent data sources, funded qualitative interviews to gather more information, and conducted a novel empirical analysis to deepen our confidence.

In this episode, based on a conversation originally aired on GiveWell’s internal podcast for staff, GiveWell’s co-founder and CEO Elie Hassenfeld provides additional context while GiveWell’s Chief Research and Program Officer Teryn Mattox dives deep into the details with Program Director Alex Cohen and Researcher Steven Brownstone, examining how we conducted the lookback, what we found, and how what we learned may shape our future nets grantmaking. 

Elie, Teryn, Alex, and Steven discuss:

• A more expansive and rigorous approach to evaluating past grants. This lookback draws on three independent quantitative sources—AMF’s monitoring data, a recent Demographic and Health Survey (DHS) conducted in the DRC, and an original survey commissioned by GiveWell—alongside qualitative research involving in-depth interviews with people involved in DRC’s net distribution system, from health zone administrators to village focus groups. 
• Conducting a novel mortality analysis using DHS microdata. Because net campaigns roll out on staggered schedules across DRC’s provinces, we were able to use the timing of children’s births relative to the date of local net campaigns as a natural experiment. We compared mortality risk for children based on when they were born, and thus the length of time they had protection from a net, and found that the net campaigns reduced the risk of death by around a quarter. That finding provides additional support for the mortality effect estimate we use in our cost-effectiveness models.
• What qualitative research revealed. Interviewers asked people across five provinces in DRC whether households received nets and whether households were using nets—and in cases where they either didn’t receive nets or weren’t using them, why not. Although we heard some anecdotes of misuse or diversion of nets, the data suggested overall that the nets are highly valued by the communities receiving them. 
• How durability data could inform campaign design. Our analysis of DHS data confirmed earlier research indicating that nets in DRC degrade before they are replaced through new distributions. As a result, it’s possible that changes in DRC like more frequent campaigns or increased support of routine net distribution through other channels may increase protection. 

If you’re interested in learning more about grant lookbacks like this one—and how they’re improving our research and shaping our future funding decisions—we invite you to join our next webinar on June 9. Alex Cohen, who was featured in this episode, and Program Director Julie Faller will walk through our lookback process, what we’re learning, and how we’re applying those lessons to help more people. Learn more and register here.

This episode was recorded on April 22, 2026 and represents our best understanding at that time.
--

Glossary

Because the conversation in this episode first aired as part of GiveWell’s internal podcast for staff, there are a number of names, acronyms, and other terms that are not explained. To make it easier to follow along, we’ve provided a glossary below. 

• all-cause mortality. All-cause mortality measures the total number of deaths from any cause in a specific group of people over a specific period of time. 
• AMF. The Against Malaria Foundation, one of GiveWell’s Top Charities, collaborates with national malaria programs and other partner organizations in low- and middle-income countries to distribute insecticide-treated nets. 
• CEA. We build cost-effectiveness analyses to assess how much good can be achieved by giving money to a certain program. 
• Cox proportional hazards model. The Cox proportional hazards model is used to estimate how much different factors, such as time since an insecticide-treated net campaign, speed up or slow down the time to death. It assigns each factor a “hazard ratio,” which is a multiplier of the baseline risk of dying: a hazard ratio of 2 for smoking means that smokers face double the risk of death at any given moment compared to nonsmokers, all else equal. 
• DHS. Demographic and Health Surveys are vast, in-person surveys that ask women to recall their children’s birth and survival histories. This method provides the primary data for mortality estimates in low- and middle-income countries.
• funging. What we call “funging” (from fungibility) refers to the effect of crowding out funding that would have otherwise come from other sources.  
• insecticide-treated nets. These nets have been treated with insecticide to deter and kill the mosquitoes that transmit malaria. Distributing insecticide-treated nets, which are then hung over sleeping spaces, can be a cost-effective way of preventing malaria.
• lookbacks. Lookbacks are reviews of past grants published on the GiveWell website that assess how well they’ve met our initial estimates and what we can learn from them.
• Marakuja. Marakuja Kivu Research is a nonprofit organization in DRC that we have contracted with to conduct quantitative and qualitative surveys. 
• M&E. GiveWell asks organizations that we fund to share detailed monitoring and evaluation data on their programs to assess the quality of program implementation and whether it is reaching recipients as intended. 
• net durability. Insecticide-treated nets decay over time, both through loss of insecticide and physical wear.
• nets team. In internal conversations, this is what we sometimes call our vector control team (see below for definition).  
• OnFrontiers. OnFrontiers is a company that sets up interviews with subject matter experts around the world.  
• PDM....

Clubfoot, a congenital condition where children are born with one or both feet twisted inward, affects roughly one in 800 newborns globally. Most of those cases are in low- and middle-income countries, where only about 20% of children with clubfoot receive treatment. 

While most donations to GiveWell are directed to programs that reduce child mortality, our growing research capacity over the last several years has expanded what we’re able to evaluate and fund. One outcome of that work is that we’re better able to direct donations to highly cost-effective programs addressing disabling conditions, like clubfoot, and meaningfully improve quality of life.    

In this episode, GiveWell CEO and co-founder Elie Hassenfeld speaks with Program Officer Meika Ball about GiveWell’s grant to MiracleFeet, an organization that expands access to clubfoot treatment. Their conversation walks through MiracleFeet’s program, how we estimated its cost-effectiveness, and Meika’s recent site visit to see the program in action in Côte d’Ivoire.

Elie and Meika discuss:

• How MiracleFeet supports clubfoot treatment: Clubfoot is treated using the Ponseti method, which involves casts to correct the foot’s position, a small surgical procedure, and a period of bracing. MiracleFeet supports this treatment by partnering with local health facilities, training healthcare workers, educating local communities about clubfoot, providing treatment materials, and working with Ministries of Health. Because of this support, treatment is provided at no cost to patients or their caregivers. GiveWell-funded independent surveys in Côte d’Ivoire and Chad indicated that very few children with clubfoot were being treated before the program, and hundreds have been enrolled since the program’s launch.
• What we learned from a recent site visit: Two GiveWell staff members recently traveled to Côte d’Ivoire to visit health facilities and see children being treated through MiracleFeet’s program. We spoke with a range of stakeholders, including healthcare workers, implementing partners, representatives from the Ministry of Health, caregivers of children receiving treatment, and disability advocates. Seeing the program in action increased our confidence that it is leading more children with clubfoot to receive treatment and is having an important impact on their lives. We also saw early signs of the program being integrated into national health systems, such as clubfoot being added to a maternal child health booklet that parents and midwives review after a child is born. 
• What makes this grant different: Most of GiveWell’s grantmaking focuses on preventing child deaths from widespread conditions like malaria or diarrhea. Clubfoot is a relatively rare condition that causes disability, not death. The treatment costs more per child than many other programs we fund, such as distributing vitamin A supplements or malaria nets, and requires sustained caregiver adherence over several years. To assess this grant opportunity, GiveWell applied moral weights, or subjective valuations, for the impact of clubfoot so it could be compared with other programs’ outcomes. We also made a separate grant to support monitoring and evaluation of the program to assess how much MiracleFeet’s support increases the number of children receiving appropriate and effective treatment. 

Our ability to evaluate, fund, and monitor a program like MiracleFeet’s is possible because of years of investment in our research team. This program exemplifies how our growing capacity is enabling us to expand our search for cost-effective opportunities where donors can do exceptional good.

Visit our All Grants Fund page to learn more about how you can support this work, and listen or subscribe to our podcast for our latest updates.

This episode was recorded on March 30, 2026 and represents our best understanding at that time.

Vitamin A supplementation is one of the programs GiveWell has supported the longest, and we’re currently funding it in many African countries. The program has an unusually strong evidence base for reducing child mortality, with multiple randomized controlled trials. Yet, as is the case for most global health programs, the evidence for vitamin A supplementation has complex, unresolved questions, such as how well findings from decades-old trials apply today and the extent to which existing research has been influenced by publication bias. As GiveWell’s research team has grown over the last several years, we have expanded our capacity to carefully research these questions. 

In this episode, GiveWell CEO and co-founder Elie Hassenfeld speaks with Senior Researcher Stephan Guyenet about the evidence base for vitamin A supplementation, the complications in applying that evidence to our funding decisions, and how GiveWell has improved our cost-effectiveness estimates for the program.

Elie and Stephan discuss:

• The evidence base for vitamin A supplementation: Evidence from rigorous trials shows that vitamin A supplementation can significantly reduce child mortality. However, most of these trials were conducted 30 to 40 years ago, when infectious disease rates and vitamin A deficiency were more prevalent, and a more recent large trial in India found a much smaller effect. As a result, we worked to resolve our uncertainties about the effect of vitamin A supplementation in the contexts where we’re supporting it today. 
• How GiveWell worked through the complications: To address our questions about the existing evidence, we engaged in further research. This included an analysis focused on the specific diseases for which vitamin A supplementation reduces mortality, a novel dosing-frequency analysis conducted in consultation with an outside statistician, and an assessment of possible publication bias. 
• What all of this means for grantmaking: While the trials report that vitamin A supplementation reduces the risk of death by 19% on average in children 6 to 59 months old, we estimate that the impact in the modern settings we model is smaller: a 1% to 11% lower risk of death. Nevertheless, we still think vitamin A supplementation can be highly cost-effective. Using our updated cost-effectiveness analysis, we estimate our most recent grant for vitamin A supplementation to Helen Keller Intl is 25 times more cost-effective than our benchmark. This change reflects our more precise, location-specific analyses that allows us to direct funding to places where vitamin A supplementation is likely to be the most cost-effective. 

GiveWell continues to scrutinize the programs we fund, including those we have supported for years. In this case, years of rigorous research have largely held up the case for vitamin A supplementation. We will continue to review the program, funding new research to address remaining uncertainties and exploring whether a new randomized trial might be feasible. By doing so, we’ll continue to increase our confidence and refine our funding decisions to target the most cost-effective locations and do the most good we can with donors’ funds.

Visit our All Grants Fund page to learn more about how you can support this work, and listen or subscribe to our podcast for our latest updates.

This episode was recorded on March 25, 2026 and represents our best understanding at that time.

GiveWell’s primary focus has always been researching, identifying, and directing donations to programs we believe will do the most good. When GiveWell first started, we approached this by looking for organizations that were already delivering highly cost-effective, evidence-backed programs and directing funding to those programs. Over time, we were able to focus further upstream by first identifying highly cost-effective programs and then supporting the development of organizations to deliver them. 

We’ve been able to take an even more expansive view as our research team doubled in size over the last several years. In addition to our core grantmaking, we’re now funding an increased number of grants designed to provide information that we think will help us direct more funding to highly cost-effective programs in the future. This includes things like generating research about program effectiveness, scoping new promising programs, and piloting program variations.  

GiveWell has long made some grants aimed at improving our knowledge base, but this work has now grown substantially and become more systematic. In 2025, GiveWell made 18 grants, totaling approximately $39 million, that were aimed specifically at getting more information to improve future funding decisions. In our latest podcast episode, GiveWell CEO and co-founder Elie Hassenfeld speaks with Program Director Julie Faller about these “value of information” grants.

Elie and Julie discuss:

• Testing variations on cash transfers to improve cost-effectiveness: Following an initial scoping grant, GiveWell recently funded GiveDirectly to pilot three program variations aimed at increasing the economic impact of its flagship program, which provides unconditional cash transfers to very poor households. Each pilot tests a different approach to increasing impact: one provides grants to local businesses ahead of a cash transfer rollout, another targets transfers to the poorest young adults, and the third pairs transfers with footbridge construction to help remote communities access markets and services. Through these pilots, we expect to learn more about the feasibility and potential cost-effectiveness of the program variations, potentially leading to opportunities to help people in need even more.  
• Testing a delivery model for diarrhea treatment: Oral rehydration solution—an inexpensive, effective treatment for diarrhea-related dehydration—is used by far fewer children than could benefit from it. To explore whether door-to-door delivery could increase uptake, GiveWell funded a large randomized controlled trial with the Clinton Health Access Initiative in Bauchi, Nigeria. Initial results are promising, indicating that 3,000 community distributors were able to reach about 80% of households with young children—and that ORS usage increased as a result. GiveWell is now considering whether to fund this model at scale, potentially with multiple implementers.
• Collecting better data on a nutrition program in India: GiveWell has supported Fortify Health, which works to address widespread anemia in India by partnering with flour millers to fortify wheat flour with iron. GiveWell recently funded a household survey in six Indian cities to better understand how much fortified flour people are actually consuming, and who in the household is eating it. The survey provided more information about several parameters that, taken together, allowed us to resolve some uncertainty about the program’s cost-effectiveness. We used what we learned to inform our decision to renew funding for the program.  

These examples reflect a longer-term shift at GiveWell—from an organization that primarily evaluated existing programs to one that increasingly generates the evidence needed to improve its grantmaking and fund more impactful programs in the future.

Visit our All Grants Fund page to learn more about how you can support this work, and listen or subscribe to our podcast for our latest updates.

This episode was recorded on March 13, 2026 and represents our best understanding at that time.

GiveWell aims to find and fund programs that will do the most good per dollar. To do this, we carefully evaluate potential grants before making them—assessing academic evidence, building cost-effectiveness models, and talking to people in the sector who know the program well. 

But our work doesn’t stop there. When a program we’ve supported nears the end of their funding, we also regularly evaluate its results to decide whether to continue our support. This typically involves gathering and analyzing extensive monitoring data. In most cases, the results are consistent with what we expected, and we renew the programs’ support. But sometimes we decide that, even if a program is doing a lot of good, it may not be having the impact we expected. In that case, we decide not to renew our support and instead direct those funds to where we think they’ll do much more good for people in need. 

In this episode, GiveWell CEO and co-founder Elie Hassenfeld speaks with Senior Program Officer Erin Crossett about the research that led GiveWell not to renew support for Evidence Action’s Dispensers for Safe Water—a program that installs chlorine dispensers at rural water points so that households can treat their drinking water and reduce waterborne disease—in Malawi and Uganda.

Elie and Erin discuss:

• How independent data revealed a significant gap in program reach: Early signals from a separate GiveWell-funded study and Evidence Action’s own internal review of the program in Kenya suggested chlorination rates were far lower than routine monitoring indicated. GiveWell then commissioned an independent survey in Uganda and Malawi to find out whether the same was true there. The survey found that only about a third as many people were using dispensers as previously estimated: roughly 2 million rather than 5 million. 
• Potential reasons for the data discrepancy: We believe that no single error drove the discrepancy. Instead, there were five or six contributing issues that together caused the differences in estimated usage. For example, chlorine was measured by matching a test result to a color wheel, which can be subjective and affected by lighting. This data was collected by Evidence Action’s own staff, which may have led them to interpret the color wheel results more favorably. 
• What GiveWell learned and its effect on future grantmaking: We believe that approving the initial grant in 2022 was the right decision, given what we knew at the time. We also think that we could have done better by, for example, investing earlier in independent verification. We now apply these lessons to our current grantmaking. For instance, our recent portfolio of safe water grants includes external surveys for all grants. 

As we've developed and grown our research team over the past several years, we’ve become increasingly able to support additional data collection, analyze and learn from our grants, and reallocate resources to the most cost-effective global health and development needs we find. 

Getting things right requires both honest self-assessment and grantee partners willing to open themselves to scrutiny, and we are grateful for Evidence Action’s partnership in identifying the discrepancy in usage rates. Evidence Action is now reducing its footprint in Uganda and Kenya, and winding down the program in Malawi, with a 24-month transition to help support communities and turn over operations to the governments where possible. 

Dispensers for Safe Water is still a program that helps people, and our grant provided clean water to millions. GiveWell’s decision not to renew reflects our mission to direct donor funds to where they will do the most good—not to fund everything that does good. We are continuing to support chlorine dispensers in contexts where we believe they will be highly cost-effective. For instance, we are currently considering a grant to Evidence Action to pilot variations of the program in northern Nigeria, where disease burden is much higher than the countries where we had been funding the program—and therefore the impact per dollar might pass our high bar for funding. 

Visit our All Grants Fund page to learn more about how you can support this work, and listen or subscribe to our podcast for our latest updates.

This episode was recorded on February 20, 2026 and represents our best understanding at that time.

Vaccines are remarkably effective at preventing deadly diseases, and, while global needs for them are great, vaccines already receive substantial global funding. This creates a challenge: How do you identify opportunities where additional funding can meaningfully increase vaccination rates and save lives?

GiveWell has long recognized the potential for highly cost-effective vaccine programs. We started supporting vaccination programs in 2015 and have made over $200 million in vaccination-related grants to date. For example, New Incentives, one of our Top Charities, aims to increase routine childhood vaccinations in northern Nigeria by providing small cash incentives to caregivers who bring their children into clinics for vaccinations. 

Over the past several years, we’ve been growing our research team and laying the groundwork to expand the scope of our work and funding. 

In this episode, GiveWell CEO and co-founder Elie Hassenfeld speaks with Senior Program Officer Natalie Crispin, who leads GiveWell’s vaccination grantmaking. They discuss how our research approach has evolved and what it means for helping more children access life-saving vaccinations.

Elie and Natalie discuss:

• Moving from finding existing programs to targeting funding gaps: In the past, GiveWell primarily looked for specific, evidence-backed program types to support—such as conditional cash transfers that incentivize vaccination. Now, with a dedicated vaccines team, we ask a bigger question: What are the bottlenecks that prevent children from getting vaccinated and how can we address them? This shift has driven our funding in areas like vaccination outreach, where teams travel to remote communities to deliver vaccines.
• Building a grantmaking portfolio to maximize learning: GiveWell recently funded several vaccination outreach programs. For example, in DRC’s Kongo Central province, where vaccination coverage rates are low, we’re supporting planning vaccination sessions (e.g. timing, frequency, location) with better data, paying community health workers to track which children need vaccines, and funding motorbikes and fuel for vaccination teams to provide vaccination near communities who are far from health facilities. This year, we hope to fund a number of additional vaccination outreach and mobile vaccination programs in differing contexts. We expect this will provide the opportunity to learn quickly about what works and help us direct future funding accordingly.
• Expanding capacity through specialization: Over the past three years, GiveWell’s research team has doubled in size and its structure has changed. Today, nearly 60 researchers work on cause-specific teams, one of which focuses on vaccination. This specialization has enabled deeper relationships with vaccination implementers, funders, and government officials—relationships that have allowed us to surface new opportunities and better understand potential funding gaps. 

GiveWell’s vaccination grantmaking is a longstanding area of focus with growing diversity and impact. The deepening expertise and novel approaches of that dedicated team illustrate how the research team as a whole has evolved to pursue opportunities we wouldn’t have been able to just a few years ago. With greater capacity and specialization across health areas, we’re now better positioned to identify and direct donations to highly cost-effective programs that save and improve lives.

Visit our Top Charities Fund and All Grants Fund pages to learn more about how you can support this work, and listen or subscribe to our podcast for our latest updates.

This episode was recorded on February 10, 2026 and represents our best understanding at that time.

Seasonal malaria chemoprevention (SMC)—a program that provides preventive antimalarial medication to young children during the months when malaria is mostly likely to be transmitted—is one of the most cost-effective programs GiveWell has identified. Malaria Consortium’s SMC program has been one of our Top Charities since 2016, and we’ve recommended more than $500 million in grants to the program.

Most of our funding to date has supported programs in West Africa, where strong evidence gives us confidence in the effectiveness of the drug combination used. In eastern and southern Africa, malaria chemoprevention programs could potentially help many more children, but we have substantial uncertainties about drug effectiveness in that region.

In this episode, GiveWell CEO and co-founder Elie Hassenfeld speaks with Senior Researcher John Macke about the CHAMP trial, a randomized controlled trial of chemoprevention drugs we’re supporting in Malawi, and how it could shape our malaria grantmaking.

This research is one example of how GiveWell is building for the future: investing in research now that could substantially expand our ability to direct funding cost-effectively in the years ahead.

Elie and John discuss:

• Why eastern and southern Africa present different challenges: One of the drugs used in seasonal chemoprevention shows widespread resistance in the region, and existing trial evidence about the effectiveness of chemoprevention there has limitations. While we’ve supported SMC in parts of Uganda and Mozambique, we’ve been cautious about scaling up without stronger evidence on which drug combinations work and whether using certain drugs could increase resistance.
• What this trial will tell us: The trial will test three drugs alone and in different combinations across roughly 7,000 children in Malawi, making it the largest individually randomized trial of chemoprevention drugs ever conducted. We’ll learn about the efficacy of the two drugs currently used in SMC, as well as an additional drug that had previously shown resistance but might now be effective again. The trial will look at the effect of the drugs on both malaria infections and hospitalizations caused by malaria.
• How the results could affect our grantmaking: Depending on what we learn, this trial could open up more than $100 million in cost-effective funding opportunities for chemoprevention programs each year in eastern and southern Africa. The trial results will also provide a knowledge base for other funders and implementers to improve the cost-effectiveness of malaria programming. We expect initial results in mid- to late 2027, with the potential for resulting grants to provide medication to children in 2028-2029.

Visit our Top Charities Fund and All Grants Fund pages to learn more about how you can support this work, and listen or subscribe to our podcast for our latest updates.

This episode was recorded on January 22, 2026 and represents our best understanding at that time.